Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Non-Responsive Diabetic Macular Edema
NCT04853355Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone in diabetic macular edema (DME), sponsored by Wake Forest University Health Sciences. Planned start Jul 2022; status: withdrawn.
02
Drugs
spironolactone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04853355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853355.